Selective connexin 43 (Cx43) hemichannel blocker; has no effect on gap junction coupling or Panx-1 channels. Reduces mitochondrial potassium influx in cardiomyocytes and attenuates glutamate-triggered ATP release in primary astrocytes. Modestly reduces infarct size in a mouse ischemia model.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 2 mg/ml in water|
References are publications that support the biological activity of the product.
Boengler et al (2013) Connexin 43 impacts on mitochondrial potassium uptake. Front Pharmacol. 4 PMID: 23760924
Wang et al (2013) Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res.Cardiol. 108 309 PMID: 23184389
Abudara et al (2014) The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front Cell Neurosci. 8 PMID: 25374505
If you know of a relevant reference for Gap19, please let us know.
View Related Products by Product Action
Keywords: Gap19, Gap19 supplier, Selective, Cx43, hemichannels, blockers, blocks, Connexin43, Panx-1, gap, junctions, Gap, Channels, 5353, Tocris Bioscience
Citations for Gap19
Citations are publications that use Tocris products.
Currently there are no citations for Gap19. Do you know of a great paper that uses Gap19 from Tocris? Please let us know.
Reviews for Gap19
There are currently no reviews for this product. Be the first to review Gap19 and earn rewards!
Have you used Gap19?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.